Novo Nordisk Inks $600M Obesity Therapy Deal with Metaphore Biotechnologies

loading Novo Nordisk Inks $600M Obesity Therapy Deal with Metaphore Biotechnologies

Novo Nordisk has entered into a collaborative agreement with Metaphore Biotechnologies, a company founded by Flagship Pioneering, to develop up to two therapeutic candidates targeting obesity management. The collaboration is set to utilize Metaphore's proprietary MIMICTM technology platform, which focuses on the design of novel compounds that can mimic the essential features of pharmacophores – the parts of a molecule responsible for its biological action. This collaboration is part of a larger strategic alliance between Novo Nordisk and Flagship Pioneering aimed at generating novel treatments for cardiometabolic and rare diseases.

Under the terms of the agreement, Novo Nordisk will provide up to $600 million, comprising an undisclosed upfront payment, potential development, and commercial milestone payments, as well as tiered royalties on the annual net sales of any licensed products. Metaphore, in conjunction with Flagship's in-house drug development unit Pioneering Medicines, will advance the multitarget therapeutics through preclinical development. Following this, Novo Nordisk has the option to proceed with clinical studies.

This partnership represents the third collaboration under the broader alliance between Novo Nordisk and Flagship Pioneering, following similar agreements with Omega Therapeutics and Cellarity. The focus on obesity treatments aligns with the growing global demand for effective weight management solutions, with the market for such drugs projected to expand significantly in the coming years.

Summary

Other news in health